Gastroenterology Genetics Panel
The Gastroenterology Genetics Panel is a targeted Next-Generation Sequencing (NGS) assay designed to comprehensively profile germline mutations in genes governing digestive tract architecture, mucosal immunity, enzymatic pathways, and hepatobiliary function. Genetic variations play a crucial role in early-onset gastrointestinal disorders, hereditary polyposis/cancer syndromes, chronic pancreatitis, and metabolic liver diseases. This panel resolves diagnostic ambiguity in complex GI conditions, providing actionable insights for cancer surveillance, targeted pharmacotherapy, endoscopic monitoring, and cascade family testing.
Key Features & Advantages
- Early Detection of Hereditary GI Cancer & Polyposis: Identifies high-risk predisposition syndromes (e.g., FAP, Lynch Syndrome, Peutz-Jeghers) prior to polyp transformation or malignant conversion, enabling timely endoscopic surveillance and prophylactic interventions.
- Definitive Diagnosis in Very Early-Onset IBD (VEO-IBD): Pinpoints monogenic immunodeficiencies underlying severe, treatment-resistant infantile or pediatric IBD, guiding targeted biological therapies or hematopoietic stem cell transplantation (HSCT).
- Elucidates Unexplained Pancreatitis & Hepatobiliary Diseases: Identifies the underlying molecular etiology in recurrent idiopathic pancreatitis and unexplained cholestasis/cirrhosis (e.g., PRSS1, SPINK1, ATP8B1), preventing exhaustive diagnostic odysseys.
- Cascade Family Screening: Enables precise, cost-effective carrier and predictive testing for first-degree relatives once a pathogenic variant is identified in the proband.
Gastroenterology NGS Panel vs. Conventional GI Diagnostics
| Feature | Gastroenterology Genetics Panel (NGS) | Standard GI Diagnostics (Endoscopy, Colonoscopy, Biopsy) |
| Diagnostic Scope | Genes regulating epithelial integrity, immunity, and enzymes | Mucosal erosion, structural lesions, and tissue histology |
| Etiological Resolution | High (Pinpoints direct molecular cause and cancer predisposition) | Phenotypic (Detects existing lesions/inflammation, not root cause) |
| Invasiveness & Risk | Non-invasive (Peripheral blood or saliva sample) | Invasive (Requires sedation; risk of perforation or bleeding) |
| Predictive Capacity | High (Detects malignancy/polyposis risk years before onset) | None (Evaluates present structural state only) |
| Targeted Therapeutics | Directs curative HSCT or biologics in monogenic VEO-IBD | Standard symptom-driven anti-inflammatory/immunosuppressive regimens |
Key Applications
- Hereditary GI Malignancies & Polyposis Syndromes: Profiling Familial Adenomatous Polyposis (FAP - APC), MAP (MUTYH), Peutz-Jeghers (STK11), Juvenile Polyposis (SMAD4, BMPR1A), and Hereditary Diffuse Gastric Cancer (CDH1).
- Very Early-Onset Inflammatory Bowel Disease (VEO-IBD): Screening for monogenic defects in IL10, IL10RA, IL10RB, XIAP, and NCF1.
- Hereditary Pancreatitis & Exocrine Insufficiency: Genetic testing for PRSS1, SPINK1, CFTR, and CTRC variants.
- Inherited Hepatobiliary & Metabolic Liver Diseases: Screening for Progressive Familial Intrahepatic Cholestasis (PFIC - ATP8B1, ABCB11, ABCB4), Wilson Disease (ATP7B), and Alpha-1 Antitrypsin Deficiency (SERPINA1).
The Nucleus Genetics Advantage: Combining ultra-deep NGS target panels fully aligned with NCCN and ECCO guidelines, advanced bioinformatic pipelines, and multidisciplinary curation by medical geneticists and gastroenterologists, we convert complex GI genomic data into actionable clinical strategies.
Get Information About This Service
Our expert team is ready to answer your questions and offer tailored solutions.
Contact Form →